4 Reasons to Worry About Vertex Pharmaceuticals -- Debunked
Some investors might be at least a little more nervous about Vertex Pharmaceuticals (NASDAQ: VRTX) now than they were only a few days ago. Why? The big biopharmaceutical company provided its third-quarter update after the market close on Monday.
What are investors' specific concerns? How serious are those concerns? Here are four reasons some might worry about Vertex -- and how those reasons are easily debunked.
The obvious reason to worry after Vertex's Q3 update is that the company missed Wall Street's revenue estimate. There were quite a few articles published Monday evening and Tuesday highlighting this fact. But it's important to keep four things in mind.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
Die Aktie ist durchaus ein Favorit unsere Community mit 57 Buy-Einschätzungen und 2 Sell-Einschätzungen.
Ein leichtes Potenzial nach oben für Vertex Pharmaceuticals Inc. mit einem Kursziel von 440 € gegenüber dem aktuellen Kurs von 432.65 €.